Prognostic value of the international Scoring System and response in patients with advanced Waldenström macroglobulinemia

Haematologica

Volumn 96, Issue 5, 2011, Pages 785-788

  Hivert, Bénédicte ^a   Tamburini, Jérome ^b,c   Vekhoff, Anne ^c   Tournilhac, Olivier ^d   Leblond, Véronique ^b   Morel, Pierre ^a,e  

^a Centre Hospitalier de LENS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d HÔTEL DIEU   (France)

^e UNIV LILLE   (France)

Author keywords

Prognostic factors and fludarabine; Waldenstr m's macroglobulinemia

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN M; PREDNISONE; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL SCORING SYSTEM FOR WALDENSTROEM MACROGLOBULINEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PROGNOSTIC VALUE; RELAPSE; SALVAGE THERAPY; SCORING SYSTEM; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 79955742272     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.029140     Document Type: Article

References (12)

1. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27(1):120-6.
2. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163-70.
3. Tamburini J, Levy V, Chaleteix C, Fermand JP, Delmer A, Stalniewicz L, et al. Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients. Leukemia. 2005(10);19:1831-4.
4. Vargaftig J, Pegourié-Bandelier B, Mahé B, Le Gouill S, Brottier- Mancini E, Delarue R, et al. Fludarabine Plus Cyclophosphamide and Rituximab (RFC) in Waldenström's Macroglobulinemia (WM): Results in 21 Patients (pts). Blood. 2006;108(suppl I):4727a (Abstr).
5. Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood. 2009;113(16): 3673-8.
6. Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006(5);6:380-3.
7. Tam C, Seymour JF, Brown M, Campbell P, Scarlett J, Underhill C, et al. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica. 2005(5);90:700-2.
8. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007(22);25:3344-9.
9. Levy V, Morel P, Porcher R, Chevret S, Wattel E, Leblond V. Advanced Waldenstrom's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis. Haematologica. 2005(2);90:279-81.
10. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009(2);27:250-5.
11. Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV. Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol. 2009(5);147:677-80.
12. Garnier A, Robin M, Larosa F, Golmard JL, Le Gouill S, Coiteux V, et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica. 2010(6);95:950-5.